The Enterprise Value as of September 2024 (TTM) for Allogene Therapeutics, Inc. (ALLO) is 427.50M

According to Allogene Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 427.50M. This represents a change of -24.22% compared to the average of 564.13M of the last 4 quarters.

Allogene Therapeutics, Inc. (ALLO) Historical Enterprise Value (quarterly & annually)

How has ALLO Enterprise Value performed in the past?

The mean historical Enterprise Value of Allogene Therapeutics, Inc. over the last ten years is 1.34B. The current 427.50M Enterprise Value has changed 3.08% with respect to the historical average. Over the past ten years (40 quarters), ALLO's Enterprise Value was at its highest in in the June 2020 quarter at 4.71B. The Enterprise Value was at its lowest in in the December 2017 quarter at 0.

Allogene Therapeutics, Inc. (ALLO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Allogene Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Allogene Therapeutics, Inc. (ALLO) Average Enterprise Value

How has ALLO Enterprise Value performed in the past?

The current Enterprise Value of Allogene Therapeutics, Inc. (ALLO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Allogene Therapeutics, Inc. (ALLO) Enterprise Value vs. Peers

How is ALLO’s Enterprise Value compared to its peers?

Allogene Therapeutics, Inc.’s Enterprise Value is greater than G1 Therapeutics, Inc. (408.99M), less than Heron Therapeutics, Inc. (433.33M), less than Annexon, Inc. (480.41M), greater than Sangamo Therapeutics, Inc. (151.85M), less than Beam Therapeutics Inc. (1.79B), less than Sana Biotechnology, Inc. (1.08B), greater than Caribou Biosciences, Inc. (144.89M), greater than Editas Medicine, Inc. (270.35M), greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than aTyr Pharma, Inc. (138.44M), less than Relay Therapeutics, Inc. (752.45M), greater than Century Therapeutics, Inc. (138.60M), less than Blueprint Medicines Corporation (6.16B), less than Intellia Therapeutics, Inc. (1.98B), greater than Verve Therapeutics, Inc. (404.46M), greater than Prime Medicine, Inc. (412.09M), greater than iTeos Therapeutics, Inc. (294.94M), less than Icosavax, Inc. (713.87M), less than Mirati Therapeutics, Inc. (3.91B), less than VectivBio Holding AG (848.58M),

Build a custom stock screener for Allogene Therapeutics, Inc. (ALLO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Allogene Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Allogene Therapeutics, Inc. (ALLO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Allogene Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.